ADC Innovation Trend — More Reliable Site-Specific Conjugation Technologies
Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker[1]. It has lower toxicity and higher anticancer activity, as well as higher stability, allowing patients to receive better anticancer therapeutics. There have been 15 ADCs received market approval so far worldwide. The global market size is estimated to reach USD 32.1 billion by 2028.
The success of ADC drug development is largely determined by the conjugation technology. Typical conjugation approaches include non-site specific conjugation and site-specific conjugation techniques. Site-specific methods to modify antibodies produce homogeneous and well-defined conjugates without compromising the conjugate’s biological activity, representing a significant trend in recent years[2-3].
Fig.1 The characteristics of various conjugation methods applied for ADC[1]
ChemExpress ADC Conjugation Capacity
ChemExpress R&D team employs multiple methods for the synthesis of bioconjugates between payloads and macromolecules .Our bioconjugation experience includes various carriers, and we offer an extensive library of linkers and payloads for your R&D purposes, as demonstrated below.
ChemExpress ADC Analytical Platform
At ChemExpress, we utilize in-house expertise and state-of-the-art analytical equipment to characterize distinct intermediates, such as proteins/mAbs, payloads, and linkers. Methods employed to assess and characterize these complex bioconjugated molecules include.
References:
[1] Sig Transduct Target Ther. 2022
[2] Angew Chem Int Ed Engl. 2021
[3] Antibody Therapeutics, 2020